×
S&P 500   3,777.92 (-1.24%)
DOW   30,586.53 (-1.64%)
QQQ   281.98 (-0.05%)
AAPL   139.47 (+0.39%)
MSFT   257.49 (-0.81%)
META   164.52 (+2.81%)
GOOGL   2,205.11 (+1.40%)
AMZN   112.07 (+2.29%)
TSLA   681.37 (-0.06%)
NVDA   146.70 (+1.01%)
NIO   21.73 (+1.73%)
BABA   115.86 (-0.12%)
AMD   74.25 (+0.79%)
MU   55.39 (+3.24%)
CGC   2.63 (-6.41%)
T   20.88 (-2.02%)
GE   60.93 (-4.11%)
F   10.97 (-3.09%)
DIS   95.01 (-1.18%)
AMC   12.72 (-5.99%)
PFE   50.50 (-3.46%)
PYPL   73.20 (+2.52%)
NFLX   182.32 (+1.32%)
S&P 500   3,777.92 (-1.24%)
DOW   30,586.53 (-1.64%)
QQQ   281.98 (-0.05%)
AAPL   139.47 (+0.39%)
MSFT   257.49 (-0.81%)
META   164.52 (+2.81%)
GOOGL   2,205.11 (+1.40%)
AMZN   112.07 (+2.29%)
TSLA   681.37 (-0.06%)
NVDA   146.70 (+1.01%)
NIO   21.73 (+1.73%)
BABA   115.86 (-0.12%)
AMD   74.25 (+0.79%)
MU   55.39 (+3.24%)
CGC   2.63 (-6.41%)
T   20.88 (-2.02%)
GE   60.93 (-4.11%)
F   10.97 (-3.09%)
DIS   95.01 (-1.18%)
AMC   12.72 (-5.99%)
PFE   50.50 (-3.46%)
PYPL   73.20 (+2.52%)
NFLX   182.32 (+1.32%)
S&P 500   3,777.92 (-1.24%)
DOW   30,586.53 (-1.64%)
QQQ   281.98 (-0.05%)
AAPL   139.47 (+0.39%)
MSFT   257.49 (-0.81%)
META   164.52 (+2.81%)
GOOGL   2,205.11 (+1.40%)
AMZN   112.07 (+2.29%)
TSLA   681.37 (-0.06%)
NVDA   146.70 (+1.01%)
NIO   21.73 (+1.73%)
BABA   115.86 (-0.12%)
AMD   74.25 (+0.79%)
MU   55.39 (+3.24%)
CGC   2.63 (-6.41%)
T   20.88 (-2.02%)
GE   60.93 (-4.11%)
F   10.97 (-3.09%)
DIS   95.01 (-1.18%)
AMC   12.72 (-5.99%)
PFE   50.50 (-3.46%)
PYPL   73.20 (+2.52%)
NFLX   182.32 (+1.32%)
S&P 500   3,777.92 (-1.24%)
DOW   30,586.53 (-1.64%)
QQQ   281.98 (-0.05%)
AAPL   139.47 (+0.39%)
MSFT   257.49 (-0.81%)
META   164.52 (+2.81%)
GOOGL   2,205.11 (+1.40%)
AMZN   112.07 (+2.29%)
TSLA   681.37 (-0.06%)
NVDA   146.70 (+1.01%)
NIO   21.73 (+1.73%)
BABA   115.86 (-0.12%)
AMD   74.25 (+0.79%)
MU   55.39 (+3.24%)
CGC   2.63 (-6.41%)
T   20.88 (-2.02%)
GE   60.93 (-4.11%)
F   10.97 (-3.09%)
DIS   95.01 (-1.18%)
AMC   12.72 (-5.99%)
PFE   50.50 (-3.46%)
PYPL   73.20 (+2.52%)
NFLX   182.32 (+1.32%)
NYSEAMERICAN:NAVB

Navidea Biopharmaceuticals Stock Forecast, Price & News

$0.67
-0.01 (-1.33%)
(As of 07/5/2022 12:02 PM ET)
Add
Compare
Today's Range
$0.66
$0.67
50-Day Range
N/A
52-Week Range
$0.56
$1.96
Volume
1,350 shs
Average Volume
218,610 shs
Market Capitalization
$20.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Navidea Biopharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.23% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

0.72 out of 5 stars

30 days | 90 days | 365 days | Advanced Chart

Receive NAVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Navidea Biopharmaceuticals logo

About Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Stock

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

NAVB Stock News Headlines

Here's what to expect from Navidea Biopharmaceuticals's earnings
See More Headlines

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NYSEAMERICAN:NAVB
Previous Symbol
NYSEMKT:NAVB
CUSIP
63937X10
Employees
11
Year Founded
N/A

Company Calendar

Last Earnings
5/12/2022
Today
7/05/2022
Next Earnings (Estimated)
8/09/2022
Fiscal Year End
12/31/2022

Profitability

Net Income
$-10,720,000.00
Net Margins
-1,557.43%
Pretax Margin
-1,555.14%

Debt

Sales & Book Value

Annual Sales
$920,000.00
Book Value
$0.46 per share

Miscellaneous

Free Float
20,407,000
Market Cap
$20.34 million
Optionable
Optionable
Beta
1.73














Navidea Biopharmaceuticals Frequently Asked Questions

Are investors shorting Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals saw a decrease in short interest in the month of June. As of June 15th, there was short interest totaling 69,500 shares, a decrease of 16.3% from the May 31st total of 83,000 shares. Based on an average trading volume of 355,500 shares, the short-interest ratio is presently 0.2 days.
View Navidea Biopharmaceuticals' Short Interest
.

When is Navidea Biopharmaceuticals' next earnings date?

Navidea Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Navidea Biopharmaceuticals
.

How were Navidea Biopharmaceuticals' earnings last quarter?

Navidea Biopharmaceuticals, Inc. (NYSEAMERICAN:NAVB) posted its quarterly earnings data on Thursday, May, 12th. The biopharmaceutical company reported ($0.10) EPS for the quarter. Navidea Biopharmaceuticals had a negative net margin of 1,557.43% and a negative trailing twelve-month return on equity of 116.36%.
View Navidea Biopharmaceuticals' earnings history
.

Who are Navidea Biopharmaceuticals' key executives?

Navidea Biopharmaceuticals' management team includes the following people:
  • Ms. Erika L. Eves, VP of Fin. & Admin. (Age 52, Pay $213.25k)
  • Dr. Michael Stanley Rosol Ph.D., Sr. VP & Chief Medical Officer (Age 54, Pay $336.31k)
  • Mr. Jeffrey G. Smith, VP of Operations

What other stocks do shareholders of Navidea Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Navidea Biopharmaceuticals investors own include OPKO Health (OPK), Ampio Pharmaceuticals (AMPE), CorMedix (CRMD), Catalyst Pharmaceuticals (CPRX), FuelCell Energy (FCEL), Palatin Technologies (PTN), Trevena (TRVN), Agenus (AGEN), Dynavax Technologies (DVAX) and Genocea Biosciences (GNCA).

What is Navidea Biopharmaceuticals' stock symbol?

Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB."

How do I buy shares of Navidea Biopharmaceuticals?

Shares of NAVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Navidea Biopharmaceuticals' stock price today?

One share of NAVB stock can currently be purchased for approximately $0.67.

How much money does Navidea Biopharmaceuticals make?

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) has a market capitalization of $20.34 million and generates $920,000.00 in revenue each year. The biopharmaceutical company earns $-10,720,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis.

How many employees does Navidea Biopharmaceuticals have?

Navidea Biopharmaceuticals employs 11 workers across the globe.

How can I contact Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The official website for Navidea Biopharmaceuticals is www.navidea.com. The biopharmaceutical company can be reached via phone at (614) 793-7500, via email at ir@navidea.com, or via fax at 614-793-7522.

This page (NYSEAMERICAN:NAVB) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.